Cellinfinity Bio

Cellinfinity Bio, seed-funded in 2024, operates in New Haven, CT, and San Francisco, CA. Founded from Sidi Chen’s (Yale University) parallel gene editing technologies, the company has used an unbiased evolution strategy using large/whole-genome CRISPR screens within CAR-T cells and CAR-NK (each cell with unique gain-of-function or loss-of-function of a specific gene). Following selection, it identifies ‘winning’ cells – those with improved specific biologic properties especially needed to combat solid tumors. These identified gene enhancements are incorporated into our novel cell therapy-based products via two approaches: 1) ex vivo autologous CAR-T (or CAR-NK) and 2) in vivo (in situ) CAR-T.